Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Fineline Cube Jul 28, 2026
Company Drug

Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment

Fineline Cube Mar 6, 2025

China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) has received approval from the National Medical Products...

Company Drug

CSPC Pharma’s JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced clinical approval from the National Medical...

Company

Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth

Fineline Cube Mar 6, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues...

Company Medical Device

Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan

Fineline Cube Mar 6, 2025

China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries...

Company Medical Device

Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval

Fineline Cube Mar 6, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies

Fineline Cube Mar 6, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered...

Company

Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way

Fineline Cube Mar 6, 2025

German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7%...

Company

NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients

Fineline Cube Mar 6, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...

Company Drug

Antengene’s Xpovio Receives Marketing Approval in Indonesia

Fineline Cube Mar 6, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...

Company Medical Device

Sino Medical Sciences’ HT Supreme Stent System Gains Vietnamese Marketing Approval

Fineline Cube Mar 6, 2025

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) announced that it has received marketing approval...

Company Deals

Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China

Fineline Cube Mar 6, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),...

Policy / Regulatory

Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown

Fineline Cube Mar 6, 2025

In a momentous address at the Third Session of the 14th National People’s Congress on...

Company Drug

RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval

Fineline Cube Mar 6, 2025

China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval...

Company Deals

Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies

Fineline Cube Mar 6, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...

Company Deals

Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs

Fineline Cube Mar 6, 2025

China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd...

Company Deals

Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China

Fineline Cube Mar 6, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an...

Company Drug

Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study

Fineline Cube Mar 6, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...

Company Deals

CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...

Company Drug

Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial

Fineline Cube Mar 6, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...

Posts pagination

1 … 235 236 237 … 700

Recent updates

  • InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial
  • Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China
  • Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials
  • GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
  • Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Company Drug

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.